| Title |
New modalities of cancer treatment for NSCLC: focus on immunotherapy
|
|---|---|
| Published in |
Cancer Management and Research, February 2014
|
| DOI | 10.2147/cmar.s57550 |
| Pubmed ID | |
| Authors |
Marianne Davies |
| Abstract |
Recent advances in the understanding of immunology and antitumor immune responses have led to the development of new immunotherapies, including vaccination approaches and monoclonal antibodies that inhibit immune checkpoint pathways. These strategies have shown activity in melanoma and are now being tested in lung cancer. The antibody drugs targeting cytotoxic T-lymphocyte-associated antigen-4 and programmed cell death protein-1 immune checkpoint pathways work by restoring immune responses against cancer cells, and are associated with unconventional response patterns and immune-related adverse events as a result of their mechanism of action. As these new agents enter the clinic, nurses and other health care providers will require an understanding of the unique efficacy and safety profiles with immunotherapy to optimize potential patient benefits. This paper provides a review of the new immunotherapeutic agents in development for lung cancer, and strategies for managing patients on immunotherapy. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 145 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | <1% |
| France | 1 | <1% |
| Brazil | 1 | <1% |
| United Kingdom | 1 | <1% |
| Korea, Republic of | 1 | <1% |
| Unknown | 140 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 27 | 19% |
| Researcher | 18 | 12% |
| Student > Ph. D. Student | 17 | 12% |
| Student > Master | 17 | 12% |
| Other | 14 | 10% |
| Other | 21 | 14% |
| Unknown | 31 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 44 | 30% |
| Biochemistry, Genetics and Molecular Biology | 23 | 16% |
| Agricultural and Biological Sciences | 15 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 6% |
| Immunology and Microbiology | 6 | 4% |
| Other | 13 | 9% |
| Unknown | 35 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 34. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 March 2021.
All research outputs
#1,004,510
of 22,743,667 outputs
Outputs from Cancer Management and Research
#18
of 1,992 outputs
Outputs of similar age
#12,227
of 307,257 outputs
Outputs of similar age from Cancer Management and Research
#1
of 11 outputs
Altmetric has tracked 22,743,667 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,992 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 307,257 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.